Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Condition: Prostate Cancer


  • Biological: PROSTVAC-V
  • Biological: PROSTVAC-F
  • Drug: MSB0011359C (M7824)
  • Biological: CV301

Purpose: Background: Some people with prostate cancer have a rise in prostate-specific antigen (PSA). This can happen even after treatments like radiation and surgery. Androgen deprivation therapy (ADT) drugs and close monitoring are one standard way to treat this group of people. Another way is to monitor people and their PSA values over time. Researchers want to see if a combination of new drugs can help these people. Objective: To see if the combination treatment of PROSTVAC, CV301, and MSB0011359C (M7824) can induce an anti-tumor attack in people with biochemically recurrent prostate cancer. Eligibility: People ages 18 and older with certain kinds of prostate cancer Design: Participants will be screened with – Medical history – Physical exam – Blood and urine tests – A scan of the neck, chest, abdomen, and pelvis – A bone scan A sample of tissue that was already taken will be tested. This will confirm the diagnosis, stage, and disease status. Some participants will have close monitoring with four monthly PSA checks. All participants will get two study drugs as shots under the skin. They will get the third drug in a vein. They will get the drugs over at least 7 months. Their vital signs will be checked before they get the drugs and for up to 1 hour after. Participants will have frequent study visits. They will have physical exams, urine and blood tests, and scans. Participants will return to the clinic about 4 weeks after they stop taking the study drugs. They will have a medical history, physical exam, and blood tests. They may also have long-term follow-up visits.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03315871

Sponsor: National Cancer Institute (NCI)

Primary Outcome Measures:

  • Measure: determine if combination immunotherapy can result in 30% decline in PSA
  • Time Frame: 6 months , one year
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Fraction of subjects with grade 3 and grade 4 adverse events
  • Time Frame: 6 weeks
  • Safety Issue:
  • Measure: Slope of the PSA change over time
  • Time Frame: end of treatment
  • Safety Issue:

Estimated Enrollment: 34

Study Start Date: March 20, 2018

Phase: Phase 2


  • Age: minimum 18 Years maximum 100 Years
  • Gender: Male

Inclusion Criteria:

  • Histopathological documentation of prostate cancer confirmed in either the Laboratory of Pathology at the National Institutes of Health (NIH) Clinical Center, or Walter Reed National Military Medical Center prior to enrollment. If no pathologic specimen is available, patients may enroll with a pathologist s report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease.
  • Recovery to baseline from acute toxicity related to prior therapy, including surgery and radiation. (28 days removed from last systemic therapy, 14 days removed from last radiation therapy).
  • Hepatic function eligibility parameters (within 16 days before starting therapy): –Bilirubin less than or equal to 1.5 mg/dL (OR in patients with Gilbert s syndrome, a total bilirubin less than or equal to 3.0), AST and ALT less than or equal to 2.5 times upper limit of normal.
  • Adequate renal function defined by an estimated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula or by measure of creatinine clearance from 24 hour urine collection.
  • No other active malignancies within the past 36 months (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder) or life-threatening illnesses.
  • Willing to travel to the NIH for follow-up visits.
  • 18 years of age or older.
  • Able to understand and sign informed consent.
  • The effects Prostvac, CV301 and MSB0011359C on the developing human fetus are unknown. For this reason, men must agree to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) prior to study entry, for the duration of study therapy and at least four months after the last treatment administration. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.
  • Additional Inclusion Criteria Specific to Safety Lead-In Cohort
  • Castrate testosterone level (<50ng/dl or 1.7nmol /L)
  • Progressive disease at study entry defined as one or more of the following criteria occurring in the setting of castrate levels of testosterone:
  • Radiographic progression defined as any new or enlarging bone lesions or growing lymph node disease, consistent with prostate cancer OR
  • PSA progression defined by sequence of rising values separated by >1 week (2 separate increasing values over a minimum of 2ng/ml (PCWG2 PSA

Eligibility Criteria:

  • ). If patients had been on flutamide, PSA progression is documented 4 weeks or more after withdrawal. For patients on bicalutamide or nilutamide disease progression is documented 6 or more weeks after withdrawal. –Patients must agree to continuation of androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone agonist/antagonist or bilateral orchiectomy
  • ECOG performance status of 0-2 (Karnofsky >80%).
  • Hematological eligibility parameters (within 16 days before starting therapy):
  • Granulocyte count greater than or equal to 1000/mm^3
  • Platelet count greater than or equal to 100 000/mm^3
  • Hgb greater than or equal to 9 g/dL Additional Inclusion Criteria Specific to Biochemical Recurrence Cohort
  • Biochemical progression defined as follows:
  • For patients following definitive radiation therapy: a rise in PSA of greater than or equal to 2 ng/mL above the nadir (per RTOG-ASTRO consensus criteria)
  • For patients following radical prostatectomy: rising PSA after surgical procedure (patients must have a PSA greater than or equal to 0.8 ng/mL)
  • Patients must have a rising PSA as confirmed by 3 values a minimum of 1 week apart over at least a 1 month period of time.
  • Patients must have a PSA doubling time of 5-15 months.
  • ECOG performance status of 0-1 (Karnofsky greater than or equal to 80%).
  • Negative CT scan/MRI and bone scan for metastatic prostate cancer.
  • Baseline testosterone greater than or equal to 100 ng/dl.
  • PSA less than or equal to 30 ng/mL.
  • Hematological eligibility parameters (within 16 days before starting therapy):
  • Granulocyte count greater than or equal to 1000/mm3
  • Platelet count greater than or equal to 100 000/mm3
  • Hgb greater than or equal to 10 g/dL

Exclusion Criteria:

  • Immunocompromised status due to:
  • Human immunodeficiency virus (HIV) positivity.
  • Active autoimmune diseases such as Addison’s disease, Hashimoto’s thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave’s disease.
  • Patients with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function including CNS, heart, lungs, kidneys, skin, and GI tract will be allowed.
  • Patients with diabetes type I, vitiligo, or alopecia are allowed.
  • Other immunodeficiency diseases
  • Splenectomy
  • Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g. corneal transplant, hair transplant).
  • Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days before the first planned dose of investigational therapy. Use of corticosteroids with minimal systemic absorption (e.g. inhaled steroids, nasal sprays, and topical agents) is allowed.
  • Serious intercurrent medical illness that, in the judgment of the investigator, would interfere with patient s ability to carry out the treatment program.
  • Other medications used for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g. phytoestrogens and saw palmetto).
  • History of prior chemotherapy (chemotherapy allowed for lead-in cohort in castration resistant disease.)
  • History of prior immunotherapy within the last 3 years (immunotherapy allowed for lead-in cohort in castration resistant disease.)
  • Receipt of an investigational agent within 28 days (or 56 days for an antibody-based therapy) before the first planned dose of study drugs.
  • Major surgery within 4 weeks prior to enrollment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
  • Previous serious adverse reactions to smallpox vaccination
  • History of allergic reactions attributed to monoclonal antibodies (grade 3)
  • Known allergy to eggs, egg products, aminoglycoside antibiotics (e.g. gentamicin or tobramycin).
  • History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
  • History of grade greater than or equal to 2 radiation proctitis
  • Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the Day 1 vaccination: (a) children less than or equal to 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV.
  • Patients who test positive for HBV or HCV
  • Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to the first planned dose of study drugs), myocardial infarction (< 6 months prior to the first planned dose of study drugs), unstable angina, congestive heart failure (New York Heart Association Classification Class greater than or equal to II), serious cardiac arrhythmia, or uncontrolled hypertension (SBP>170/DBP>105).
  • Patients who have received a red cell transfusion within 2 weeks prior to enrollment.
  • Individual tumor lesion(s) in the liver or chest which are 10 cm or larger.
  • In the opinion of the investigator the risk of bleeding outweighs the potential benefit with M7824. Note: patients with a history of bleeding diathesis or recent (within 3 months) clinically significant bleeding events are also excluded.


  • Anna C Couvillon, C.R.N.P.
  • (240) 858-3148


  • National Institutes of Health Clinical Center
  • Bethesda Maryland 20892 United States

View trial on